醋酸亮丙瑞林联合反加替勃龙治疗子宫内膜异位症的临床疗效分析

Clinical Observation of Leuprorelin Acetate Combined with Anti-Gatiferon in the Treatment of Endometriosis

目的分析醋酸亮丙瑞林(LA)+反加替勃龙治疗子宫内膜异位症(EMS)的临床疗效.方法以2015年1月—2018年12月间入该院治疗的60例EMS患者为研究主体.分成A组和B组,均是30例.A组给予LA+反加替勃龙治疗,B组给予LA单纯治疗.对比治疗效果.结果 A组的治疗总有效率为93.33%,B组为73.33%(x^2=4.320,P=0.038).A组的各检测指标均优于B组(P<0.05).治疗后,两组的腰椎与股骨粗隆骨密度评分均低于治疗前,但A组高于B组,组间与组内骨密度对比差异有统计学意义(P<0.05).A组的不良反应发生率为10.00%,B组为33.33%(x^2=4.812,P=0.028).结论为EMS患者行LA+反加替勃龙治疗的效果较佳,可改善患者的检测指标和骨密度,且不良反应少,具有推广价值.

Objective To analyze the clinical efficacy of leuprolide acetate (LA) and anti-gatiferon in the treatment of endometriosis (EMS). Methods A total of 60 EMS patients admitted to our hospital from January 2015 to December 2018 were studied. They were divided into group A and group B, with 30 cases in each group. Group A was treated with LA + anti-gatiferone, and group B was treated with LA alone. The therapeutic effect was compared. Results The total effective rate of group A was 93.33% and that of group B was 73.33%(χ^2=4.320, P=0.038). The indexes of group A were better than those of group B(P<0.05). After treatment, the BMD scores of lumbar spine and femoral trochanter in both groups were lower than those before treatment, but those in group A were higher than those in group B. There was a statistically significant difference in BMD between and within groups (P<0.05). The incidence of adverse reactions was 10.00% in group A and 33.33% in group B(χ^2=4.812, P=0.028). Conclusion LA + anti-gatiferon treatment for EMS patients has better effect, which can improve the detection index and bone mineral density of patients. It has less adverse reactions, and has the value of promotion.